Lancet Oncology

The Lancet is a weekly peer-reviewed general medical journal. It is one of the world s best known, oldest, and most respected general medical journals. The Lancet was founded in 1823 by Thomas Wakley, an English surgeon who named it after the surgical instrument called a lancet, as well as after the term "lancet arch", a window with a sharp pointed arch, to indicate the "light of wisdom" or "to let in light". It publishes original research articles, review articles ("seminars" and "reviews"), editorials, book reviews, correspondence, as well as news features and case reports. The Lancet has been owned by Elsevier since 1991. As of 1995, the editor-in-chief is Richard Horton. The journal has editorial offices in London, New York, and Beijing. In the 2010 Journal Citation Reports, The Lancet s impact factor was ranked second among general medical journals, at 33.63, after The New England Journal of Medicine (53.48). The Lancet also has several speciality journals all bearing the parent title: The Lancet Neurology (neurology), The Lancet Oncology (oncology), and The Lancet Infectious Diseases (infectious diseases), all of which publish original research and reviews. These three

Publisher
Elsevier
History
1823–present
Impact factor
33.633 (2010)
Some content from Wikipedia, licensed under CC BY-SA

Concern at lack of teenage patients in cancer trials

Age limits on clinical trials need to be more flexible to allow more teenage cancer patients the chance to access new treatments, according to a report from the National Cancer Research Institute (NCRI), ...

Jun 30, 2014
popularity not rated yet | comments 0

Researcher discovers ovarian cancer treatment

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the ra ...

Jun 19, 2014
popularity 5 / 5 (1) | comments 0

Immunotherapy for prostate cancer in sight

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for ...

May 26, 2014
popularity 5 / 5 (2) | comments 0